15 on COVID-19 for 4/6/2020 - IL-6 Antagonists

Activity Preview

Tocilizumab for COVID-19? Tocilizumab is a drug used to treat autoimmune disorders, and yet, people are now talking about using it to treat COVID-19. Does it seem like people are just trying anything and everything to treat COVID-19? It might sound strange, but there are some interesting connections between tocilizumab, advanced cancer therapies and COVID-19 disease. Join us for today’s 15 on COVID-19 episode as we take a deeper look at these connections and explore whether tocilizumab has any utility in patients with severe COVID-19 disease

Learning Objectives

  • Discuss the latest developments related to COVID-19

Activity type: Knowledge-based
Target Audience: Pharmacists and Pharmacy Technicians
Learning Level: 2

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 0.25 contact hour of CPE credit (0.025 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-169-H01-P/T

To obtain credit for completing 15 on COVID-19 04/06/2020,  participants will need to watch the archived webinar, complete the assessment, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.    

Initial release date: April 06, 2020
Expiration date: April 06, 2021 - No credit granted after this date

Development

15 on COVID-19 04/06/2020 is an activity for pharmacists and pharamacy technicians developed by the American Pharmacists Association. © 2020 American Pharmacists Association

Disclosures

Daniel Zlott, PharmD, BCOP and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures

Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association. 

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-20-169-H01-P 0.025 CEUs April 06, 2020 - April 06, 2021
ACPE# 0202-0000-20-169-H01-T 0.025 CEUs April 06, 2020 - April 06, 2021